Article

Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains

2021-03-23

Abstract excerpt

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission with several emerging variants remain uncontrolled in many countries, indicating the pandemic remains severe. Recent studies showed reduction of neutralization against these emerging SARS-CoV-2 variants by vaccine-elicited antibodies. Among those emerging SARS-CoV-2 variants, a panel of amino acid mutations was characterized including those...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: de292b07-4034-5007-b259-295aada6dac8
DOI: 10.1101/2021.03.22.436481

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domainsDOI 10.1101/2021.03.22.436481Read

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium studySemantic proximity Read

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikeSemantic proximity Read

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.Semantic proximity Read

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.Semantic proximity Read

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.Semantic proximity Read

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodiesSemantic proximity Read

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodiesSemantic proximity Read

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read

Broadly neutralizing antibodies against COVID-19Semantic proximity Read

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsSemantic proximity Read

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.Semantic proximity Read